SCHEMBL1250934

SCHEMBL1250934

c1ccc(-c2ccc(Cn3ccc4cc(-c5nn[nH]n5)ccc43)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GP6 Q9HCN6 2/20 0.51
PLA2G4A P47712 1/20 0.48
GRM2 Q14416 1/20 0.47
HTR6 P50406 1/20 0.45
PLG P00747 1/20 0.44
PLAU P00749 1/20 0.44
CCR2 P41597 1/20 0.44
PDE7A Q13946 2/20 0.44
PDE7B Q9NP56 2/20 0.44
IDO1 P14902 1/20 0.44
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
HPGD P15428 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
AGTR1 P30556 2/20 0.43
AGTR2 P50052 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
SLC2A1 P11166 1/20 0.42
MMP13 P45452 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1250386 0.95 GRM2 (0.48) GP6PLA2G4AGRM2HTR6PLG
SCHEMBL12892290 0.92 GP6 (0.54) GP6PLA2G4AGRM2HTR6PLG
SCHEMBL12892289 0.89 PLA2G4A (0.50) PLA2G4AGRM2PLGPLAUAGTR1
SCHEMBL4096357 0.89 RPA1 (0.52) PLA2G4AGRM2PLGPLAUCCR2
SCHEMBL4104344 0.89 PLA2G4A (0.52) PLA2G4AGRM2PLGPLAUAGTR1
SCHEMBL4096473 0.88 PLA2G4A (0.49) PLA2G4AGRM2CCR2PDE7APDE7B
SCHEMBL4088566 0.88 GRM2 (0.49) PLA2G4AGRM2PLGPLAUAGTR1
SCHEMBL4089239 0.88 PLA2G4A (0.51) PLA2G4AGRM2PLGPLAUALDH1A1
SCHEMBL12914817 0.88 PLA2G4A (0.48) PLA2G4AGRM2PLGPLAUCCR2
SCHEMBL1248028 0.88 ATM (0.51) PLA2G4AGRM2PLGPLAUCCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7879893-B2 Zinc binding ligand; sustained release of insulin NOVO NORDISK A/S (DK) 2011-02-01 US disclosed
US-7879893-B2 Zinc binding ligand; sustained release of insulin NOVO NORDISK A/S (DK) 2011-02-01 US disclosed
US-7879893-B2 Zinc binding ligand; sustained release of insulin NOVO NORDISK A/S (DK) 2011-02-01 US disclosed
US-20090123563-A1 Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand NOVO NORDISK A/S (DK) 2009-05-14 US disclosed
US-20090123563-A1 Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand NOVO NORDISK A/S (DK) 2009-05-14 US disclosed
US-20090123563-A1 Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand NOVO NORDISK A/S (DK) 2009-05-14 US disclosed
EP-1585541-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER NOVO NORDISK AS (DK) 2007-11-14 EP disclosed
EP-1585541-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER NOVO NORDISK AS (DK) 2007-11-14 EP disclosed
US-20060258561-A1 Novel NPH insulin preparations NOVO NORDISK A/S (DK) 2006-11-16 US disclosed
CN-1787833-A Pharmaceutical preparation comprising acid-stabilized insulin NOVO NORDISK AS (DK) 2006-06-14 CN disclosed
US-20060069013-A1 Pharmaceutical preparations comprising acid-stabilised insulin NOVO NORDISK A/S (DK) 2006-03-30 US disclosed
US-20050065066-A1 comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability NOVO NORDISK A/S (DK) 2005-03-24 US disclosed
CN-1558762-A Novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer ŵ��Ų�ڿ˹�˾ 2004-12-29 CN disclosed
US-20030229120-A1 Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer NOVO NORDISK A/S (DK) 2003-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258561-A1 Novel NPH insulin preparations IAPP, HBB, INSR GP6 2601/4885PLA2G4A 4850/4885GRM2 3274/4885
US-20060069013-A1 Pharmaceutical preparations comprising acid-stabilised insulin IAPP, GPR119, INSR GP6 2357/4885PLA2G4A 4116/4885GRM2 2255/4885
US-20030229120-A1 Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer IAPP, IRS1, GPR119 GP6 3513/4885PLA2G4A 3743/4885GRM2 1690/4885
US-20050065066-A1 comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability IAPP, IRS1, INSR GP6 2684/4885PLA2G4A 4510/4885GRM2 2588/4885
US-20090123563-A1 Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand IAPP, IRS1, HBB GP6 1944/4885PLA2G4A 4747/4885GRM2 2426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.